VIO-01 is under clinical development by Valerio Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VIO-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VIO-01 overview

VIO-01 (formerly OX425) is under development for the treatment of metastatic solid tumors like ovarian cancer, prostate cancer, breast cancer and triple negative breast cancer. It acts by targeting poly adenosine diphosphate ribose polymerase (PARP). The drug candidate is developed based on the platON platform which comprises three components, a sequence of double-strand oligonucleotides, a linker and a cellular uptake facilitator. It is administered through intravenous route.

Valerio Therapeutics overview

Valerio Therapeutics (Valerio), formerly Onxeo SA, is a clinical-stage biotechnology company. The company is a manufacturer of drugs that offers the development and registration of orphan oncology drugs for the treatment of cancer. The company offers pipeline products including beleodaq and asidna among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer among others. In addition, the company’s beleodaq acts as an anti-cancer treatment for solid and hematology cancer. The company provides preclinical and clinical development, regulatory affairs and other services. Valerio is headquartered in Paris, France.

For a complete picture of VIO-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.